Literature DB >> 24523108

Reversible mechanisms of enzyme inhibition and resulting clinical significance.

Barbara Ring1, Steven A Wrighton, Michael Mohutsky.   

Abstract

Inhibition of a drug-metabolizing enzyme by the reversible interaction of a drug with the enzyme, thus decreasing the metabolism of another drug, is a major cause of clinically significant drug-drug interactions. This chapter defines the four reversible mechanisms of inhibition exhibited by drugs: competitive, noncompetitive, uncompetitive, and mixed competitive/noncompetitive. An in vitro procedure to determine the potential of a drug to be a reversible inhibitor is also provided. Finally, a number of examples of clinically significant drug-drug interactions resulting from reversible inhibition are described.

Mesh:

Substances:

Year:  2014        PMID: 24523108     DOI: 10.1007/978-1-62703-758-7_4

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  6 in total

Review 1.  Targeting Tyrosine Phosphatases: Time to End the Stigma.

Authors:  Stephanie M Stanford; Nunzio Bottini
Journal:  Trends Pharmacol Sci       Date:  2017-04-12       Impact factor: 14.819

2.  Cholic acid: a novel steroidal uncompetitive inhibitor against β-lactamase produced by multidrug-resistant isolates.

Authors:  Syarifah Ab Rashid; Norhaswanie Norman; Siew Hway Teo; Woei Yenn Tong; Chean Ring Leong; Wen-Nee Tan; Mohd Azizan Mohd Noor
Journal:  World J Microbiol Biotechnol       Date:  2021-08-16       Impact factor: 3.312

3.  Inhibition of Cytochrome P450s by Strobilanthes crispus Sub-Fraction (F3): Implication for Herb-Drug Interaction.

Authors:  Ya Fen Yong; Mervyn Wing On Liew; Nik Soriani Yaacob
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2022-02-11       Impact factor: 2.441

4.  Discovery of Orally Bioavailable Purine-Based Inhibitors of the Low-Molecular-Weight Protein Tyrosine Phosphatase.

Authors:  Stephanie M Stanford; Michael A Diaz; Robert J Ardecky; Jiwen Zou; Tarmo Roosild; Zachary J Holmes; Tiffany P Nguyen; Michael P Hedrick; Socorro Rodiles; April Guan; Stefan Grotegut; Eugenio Santelli; Thomas D Y Chung; Michael R Jackson; Nunzio Bottini; Anthony B Pinkerton
Journal:  J Med Chem       Date:  2021-04-29       Impact factor: 7.446

5.  Characterization of VU0468554, a New Selective Inhibitor of Cardiac G Protein-Gated Inwardly Rectifying K+ Channels.

Authors:  Allison Anderson; Baovi N Vo; Ezequiel Marron Fernandez de Velasco; Corey R Hopkins; C David Weaver; Kevin Wickman
Journal:  Mol Pharmacol       Date:  2021-09-09       Impact factor: 4.436

Review 6.  Molecular mechanisms of inhibiting glucosyltransferases for biofilm formation in Streptococcus mutans.

Authors:  Qiong Zhang; Qizhao Ma; Yan Wang; Hui Wu; Jing Zou
Journal:  Int J Oral Sci       Date:  2021-09-30       Impact factor: 6.344

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.